Lamivudine/raltegravir

Drug Profile

Lamivudine/raltegravir

Alternative Names: DUTREBIS; MK-0518/3TC; MK-0518B; Raltegravir/3TC; Raltegravir/lamivudine

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Naphthyridines; Organic chemicals; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action HIV integrase inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 26 Mar 2015 Registered for HIV-1 infections (Combination therapy, In adolescents, In adults, In children) in European Union (PO)
  • 26 Mar 2015 Registered for HIV-1 infections (Combination therapy, In adolescents, In children, In adults) in Norway, Liechtenstein, Iceland (PO)
  • 19 Mar 2015 Launched for HIV-1 infections (Combination therapy, In adolescents, In children, In adults) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top